Trial Profile

Proof of concept study in patients with Chronic Kidney Disease (CKD) grade 3 and concurrent F2/F3 MASH

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vonafexor (Primary)
Indications Non-alcoholic steatohepatitis; Renal failure
Focus Proof of concept; Therapeutic Use

Most Recent Events

19 Jun 2025 New trial record
12 Jun 2025 According to ENYO Pharma media release, company has finalized its Series C financing round with a 6 million euro investment from Vesalius Biocapital IV, bringing the total Series C raise to 32 million euro which will extend ENYO's cash runway through the second half of 2026 and enables the initiation of this proof of concept study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com